Продолжая использование сайта, вы соглашаетесь с использованием файлов cookie. Подробнее.

GRIPPOL®
QUADRIVALENT

RUSSIA'S FIRST QUADRIVALENT
INACTIVATED SUBUNIT INFLUENZA VACCINE
H1N1
5 µg
+
H3N2
5 µg
+
VICTORIA
5 µg
+
YAMAGATA
5 µg
+
ADJUVANT
AZOXIMER BROMIDE
500 µg
Grippol Quadrivalent is used for vaccination children and adults aged 6 to 60 years and over.
The vaccine is especially indicated for people:
  • with chronic heart, blood, and vascular diseases;
  • nervous system and brain diseases;
  • respiratory pathologies, including bronchial asthma, COPD, and smokers;
  • those affected by kidney disease, diabetes mellitus, and metabolic disorders, including obesity;
  • persons with autoimmune, allergic diseases (except chicken protein allergy);
  • sickly people;
  • those affected by HIV and other immunodeficiencies;
  • people who have a high risk of getting the flu or infecting others because of their occupation.

Grippol® Quadrivalent protects against 4 strains of influenza: 2 influenza A viruses (A/H1N1 and A/H3N2) and influenza B virus 2 lines (V/Yamagata and V/Victoria)
Polyoxidonium® Adjuvant in Grippol® Quadrivalent enables to decrease the number of antigens in the vaccine by a factor of 3 and ensures a pronounced and long-lasting immune response to vaccination
Grippol® Quadrivalent meets modern quality standards for influenza vaccines
  • Preservatives and Antibiotic Free
  • Available in individual syringe doses with an atraumatic needle
  • Produced according to international GMP standards
Grippol® Quadrivalent is based on the production technology of the Grippol® family of vaccines, with a broad evidence base and a long history of use of over 300 million doses, including in children from 6 months of age, the elderly, pregnant women, and persons with chronic diseases
Since 2012, WHO has been recommending annually that influenza B viruses of both Yamagata and Victoria1 strains be included in seasonal influenza vaccines.
TRIVALENT influenza vaccines contain antigens from 3 strains of influenza virus
H1N1
+
H3N2
+
VICTORIA
or
YAMAGATA

To date, only trivalent influenza vaccines have been used in the Russian Federation. In 2019, the Ministry of Health, together with Rospotrebnadzor, developed and approved a Phased Transition Plan for the use of quadrivalent vaccines to prevent influenza as part of the National Preventive Vaccination Calendar between 2019 and 2021.

Grippol®Quadrivalent contains 4 of the most common antigenic strains, which means that once it is administered and an immune response is formed, a person has a broader spectrum of protection against different types of viruses. Accordingly, the risk of contracting influenza is reduced.

4-valent influenza vaccines have greater prophylactic and pharmacoeconomic efficacy than 3-valent vaccines
According to estimates by the Center for Disease Control and Prevention for 2014-2034 (CDC, USA), the clinical outcomes and costs of replacing 3-valent with 4-valent vaccines will allow:2
to decrease the incidence of influenza В by 16 million cases
to decrease hospitalizations by 137,6 thousand cases
to decrease the number of lethal outcomes by 16,1 thousand cases
In Russia, a switch from the 3-valent to the 4-valent vaccine could prevent up to 265,8 thousand cases of influenza per season3
Quadrivalent vaccines are included in National Immunization Programs in various countries of the world4
Country/
Regulatory body
Year when the recommendation was made Age/group of vaccinated persons
WHO 2012 Pregnant, children under 5 years old, health care professionals, elderly, persons with chronic diseases
Germany 2013 Pregnant; children under 5 years old; health care professionals, elderly; persons with chronic diseases; people planning long journeys
USA 2013 Children from 6 months and adults
Hong Kong 2013 Children over the age of 3 and adults
Canada 2014 6 months and over
France 2014 Children over the age of 3 and adults
Belgium 2015 Over the age of 2
Brazil 2014 Elderly over 60 years old
Australia 2015 6 months and over
Great Britain 2013 Children 2-7 years old and children at risk 2-18 years old
GRIPPOL® QUADRIVALENT IS RUSSIA'S FIRST QUADRIVALENT INACTIVATED SUBUNIT INFLUENZA VACCINE
Изображение упаковки и вакцины ГРИППОЛ® КВАДРИВАЛЕНТ
  • Contains antigens of 2 influenza A subtypes (H1N1 and H3N2), 2 influenza B strains (Victoria and Yamaga), and the Polyoxidonium® immunoadjuvant
  • Preservatives-free
  • Available in individual syringe doses with an atraumatic needle
  • Developed by Grippol® Vaccine Technology
View package leaflet

ATTENTION!

This site contains information for medical and pharmaceutical professionals. To view the content, please, confirm that you have the appropriate qualifications

Do not show this message for 30 minutes
EXIT THE SITE